Centelles

• MK-0616-013 Not authorised
  2022-502777-42-00 5 Hypercholesterolemia
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Clinical trial of molnupiravir (MK-4482) in adults who have COVID-19 and are not hospitalized, who are at high risk for serious illness from … Recruiting
  2023-507227-36-00 5 2025-02-21 SARS-CoV-2 (COVID-19) infection
• A clinical study of enlicitide in people with high cholesterol (MK-0616-037) Ended recruitment
  2025-521495-54-00 5 2025-12-20 Hyperlipidemia
• A study to test whether vicadrostat in combination with empagliflozin helps people with chronic kidney disease Ended recruitment
  2024-518457-42-00 4 2025-08-28 chronic kidney disease
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended recruitment
  2023-504922-20-00 5 2024-08-23 Hypercholesterolemia
• An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu … Ended recruitment
  2023-509762-38-00 5 2024-08-01 Respiratory Syncytial Virus Infections
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• Effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a sin … Ended recruitment
  2023-503719-13-00 5 2024-05-06 Prevention of clinically relevant bleeding events in patients treated
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults. Ended recruitment
  2023-505255-51-00 5 2022-08-08 Herpes Zoster
• Efficacy, immunogenicity, and safety of the 9vHPV vaccine in adult males 20 to 45 years of age Ended recruitment
  2022-501974-21-00 5 2020-04-01 Prevention of oral persistent infection caused by any of the human pap
• A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® LP.8.1 against SARS-CoV-2 variants. Ended
  2025-524021-41-00 6 2025-10-28 COVID-19
• A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via MDI containing propellant HFA-1 … Ended
  2023-509001-76-00 5 2024-07-01 Asthma
• MK-0616-013 Ended
  2022-502777-42-01 5 2024-01-16 Hypercholesterolemia
• A Ph2 dose-finding study (MARS-17) to evaluate the efficacy and safety of GSK3858279 in adults with knee osteoarthritis pain. Ended
  2022-502799-22-00 4 2023-11-29 Knee osteoarthritis pain
• A Phase IIb/III, Double-Blind, Randomised, Active-Controlled, Multi-Center, Non-Inferiority Clinical Trial, to assess the safety and immunog … Ended
  2023-508458-25-00 10 2023-11-13 COVID-19 disease
• A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus f … Ended
  2023-504727-32-00 4 2023-09-18 Acute vulvovaginal candidiasis
• A phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with sea … Ended
  2023-506189-29-00 4 2023-09-04 SARS-CoV-2 and Influenza
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• Open-label, Multi-centre, Non-Inferiority study of safety and immunogenicity of BIMERVAX as heterologous booster for the prevention of coron … Ended
  2023-504639-42-00 4 2023-05-26 SARS-CoV-2 infection
• A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 Ended
  2023-504540-33-00 5 2023-03-06 COVID-19
• Safety and Immunogenicity of V116 in Adults 50 Years of Age or Older Ended
  2022-503144-40-00 5 2022-11-17 Pneumococcal disease

Showing 1–24 of 25 trials